Nouscom Is A Clinical Stage Immuno Oncology Company Founded In 2015Focused On Developing Next Generation Cancer Immunotherapiesthe Company Utilizes A Proprietary Viral Vector Platform To Create Personalized And Off The Shelf Therapies That Enhance Anti Cancer Immune Responsestheir Technology Features Non Human Primate Derived Viral Vectorssuch As Great Ape Adenovirus And Modified Vaccinia Virus Ankarawhich Are Designed To Deliver Large Payloads Of Neoantigens Or Immunomodulators While Evading Pre Existing Human Immunity The Company S Product Pipeline Includes Nous Peva Personalized Cancer Vaccine Currently In Phase 1B Trials For Melanoma And Non Small Cell Lung Cancerand Vac 85135An Off The Shelf Immunotherapy In Phase 1 Trials For Myeloproliferative Neoplasmslicensed To Janssen Research & Development And Bristol Myers Squibbnouscom Has Raised A 67 5 Million In Funding To Support Its Clinical Programs And Collaborates With Major Pharmaceutical Firms To Advance Its Researchthe Leadership Team Brings Extensive Experience From Notable Companies In The Pharmaceutical And Biotechnology Sectors
No conferences found for this company.
| Company Name | Nouscom Srl |
| Country |
Italy
|
| Address | N/A |
| Telephone | N/A |
| N/A |
